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Abstract  
The liver biopsy has long been the "gold standard" for assessing liver fibrosis in patients with hepatitis C. It’s an invasive procedure which is 
associated with an elevated bleeding, especially in chronic hemodialysis patients. Main goal is to assess liver fibrosis in chronic hemodialysis with 
HCV by Fibroscan and by biological scores (APRI, Forns and Fib-4), and to measure the correlation between these tests. Cross-sectional study 
including all chronic hemodialysis patients with hepatitis C virus, in two public hemodialysis centers of Fez. All patients were evaluated for liver 
fibrosis using noninvasive methods (FibroScan and laboratory tests). Subsequently, the correlation between different tests has been measured. 95 
chronic hemodialysis were studied, twenty nine patients (30.5%) with chronic hepatitis C. The average age was 52.38 ± 16.8 years. Nine liver 
fibrosis cases have been concluded by forns score. Fibroscan has objectified significant fibrosis in 6 cases. On the other side APRI has objectified 
sgnifivant fibrosis only in 3 cases. The Fib-4 showed severe fibrosis in five cases. The results have been most consistent between APRI and Fib-4, 
followed by Fibroscan and Forns, then APRI and FibroScan. 
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Hepatitis C virus (HCV) is the most common viral infection in chronic 
hemodialysis patients, with a high prevalence and increased risk of 
developing cirrhosis [1,2]. Liver biopsy is widely practiced and 
accepted. However, the chronic hemodialysis patients are a high risk 
of bleeding. Therefore, many alternative non invasive methods have 
been developed to assess liver fibrosis like Fibroscan and biological 
scores : fibrotest [3,4], fibrometer [5], APRI, FIB-4 and Forns. Their 
interest has been demonstrated particulary in patients with hepatitis 
C infection and normal renal function. The aim of our study is to 
assess fibrosis liver in chronic hemodialysis patients with HCV 
infection by FibroScan and biological scores (APRI, Fib-4, and 





This is a cross-sectional study, including all chronic hemodialysis 
patients with HCV infection followed in both public hemodialysis 
centers in Fez, between January and March 2011. Patients 
coinfected with HBV and HCV were excluded.  
 
The 3rd generation ELISA was used to detect anti-HCV antibodies 
then the results were confirmed by PCR. FibroScan [6] and 
abdominal ultrasound was realized for all patients with HCV by a 
single examiner in functional explorations unit of the university 
hospital Hassan II in Fez. The endoscopy was realized in cirrhosis 
cases.  
 
The diagnosis of liver cirrhosis was retained on clinical, biological 
and radiological data. The calculation is performed using the 
following formulas:  
 
APRI = AST×100/ Platelets [7]  
 
Forns =7.811-3.131 Log (Platelets) + 0.781 Log(GGT) + 3.467 Log 
(age)- 0.014(cholesterol) [8]  
 
Fib-4 = (age x ASAT) / (Platelets x ALT)  
 
Results are interpreted according to the threshold values for each 
score [9-12] (Table 1).  
 
The diagnosis of liver cirrhosis was accepted on FibroScan if the 
hepatic elasticity was higher than 12.5 kPa, and on the APRI if the 
score was higher than 1.  
 
The measure of agreement between different non-invasive tests 
(FibroScan and biological scores) [13], was based on the study of 
KAPPA coefficient of Landis and Koch [14,15]. This index is 
expressed as a numerical value corresponding to a degree of 
agreement between the parameters studied. The analysis of the 
degree of concordance across kappa index need to use the same 
coding for different biological and FibroScan scores based on a 
binary outcome "significant fibrosis" or "non-significant fibrosis" 





Among 95 hemodilaysis, twenty nine patients (30.5%) had HCV . 
The average age was 52, 38 ± 16.8 years(23-81), with a female 
predominance( sex ratio 0.71). Hypertensive nephrosclerosis was 
the main cause of end-stage renal failure (37.9%), followed by 
glomerulonephritis and diabetic nephropathy in 20% and 8.8% of 
patients respectively. The etiology remained unknown in the third of 
cases. The average duration of hemodialysis was 84± 46 months 
(12-216). The FibroScan showed a significantly fibrosis in six cas 
(27.3%), all had higher liver elasticity (<12.5 Kpa). Twenty two 
patients had no significant fibrosis. According to APRI score, 
significant fibrosis (= F2) was noted in three cases , no significant 
fibrosis (>F2) in 18 cases and an non-interpretable score for the 
remaining patients.  
 
Nine patients had a Forns< 6.9 (significant fibrosis) and five 
patients had Forns>4.2 (insignificant fibrosis ). The rest of patients 
had intermediate results. The Fib-4 test has eliminated hepatic 
fibrosis in 12 cases, only five patients had severe fibrosis (Fib-
4<3.25) (Table 2). The diagnosis of liver cirrhosis was retained in 
eight patients. Doppler abdominal has showed signs of cirrhosis 
and/or portal hypertension in these patients. The esophageal 
varices were found only in two patients. In cirrhotic patients, the 
Fibroscan has confirmed the presence of severe fibrosis in five cases 
with sensitivity of 62.5%, and specificity of 95.2%. Among these 
patients, only Four had severe fibrosis by Fib-4 test, the rest were in 
the intermediate area. However, only two patients had hepatic 
cirrhosis at APRI score. Regarding the concordance between these 
scores and FibroScan, the results were most consistent between 
APRI and Fib-4, followed by Fibroscan and Forns, then Fibroscan 
and APRI. All these concordances were classified as moderate 





According to recent guidelines, the assessment of liver fibrosis in 
patients with HCV infection without comorbidity is based on liver 
biopsy, FibroTest or FibroScan [16]. A recently published Meta-
analysis [17] included the most important publications on the 
performance of FibroScan in the evaluation of liver fibrosis in 
chronic viral hepatitis C. There was a correlation between liver 
elasticity measured by Fibroscan and the degree of fibrosis on liver 
biopsy in all studies. Fibroscan was an effective test with an 
excellent specificity and sensitivity especially in detecting of 
significant fibrosis and cirrhosis. Other scores have been studied like 
fibrotest, fibrometre, hepascore, APRI, Fib-4 and Forns. The most 
studies have shown that APRI has an important negative predictive 
value to eliminate significant fibrosis and cirrhosis. As for Fib-4, the 
major advantage was to detect patients with severe fibrosis or 
cirrhosis. Forns was performant to eliminate minimum or 
insignificant fibrosis. Few studies have been conducted in chronic 
hemodialysis patients with HCV. The first study has evaluated the 
performance of APRI in 203 hemodialysis patients (HDC) infected 
with HCV [9]. Insignificant fibrosis was eliminated a threshold >0.4 
with an 93% NPV . The threshold = 0.95 was in favor of significant 
fibrosis with an 66% PPV, and an area under the ROC curve of 
0.801. Moreover, the threshold = 0.55 eliminates the presence of 
cirrhosis with an 99% NPV. In other study published in 2010, 
including 279 hemodialysis infected with HCV. Multivariate analysis 
showed that APRI was a predictor factor of significant fibrosis [10] 
with an area under the ROC curve at 0,83. Almost half of the 
patients undergoing liver biopsy were correctly diagnosed by 
adaptation of the threshold level of APRI, which joins the results of 
the previous study on the possibility of reducing the use of liver 
biopsy in this context. In a recent study published in 2011, including 
284 hemodialysis with HCV[18]. They have showed that Fibroscan 
was better than APRI to detect significant fibrosis compared to liver 
biopsy. Indeed, the area under the ROC curve of Fibroscan was 
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greater than that of APRI for predicting patients with significant 
hepatic fibrosis(= F2) (0.96 versus 0,84 p >0.001), patients with 
advanced liver fibrosis (= F3) (0.98 versus 0.93, p = 0.04), and 
patients with cirrhosis (F4) (0.99 against 0.92 p = 0.13), using the 
following thresholds 5.3, 8.3 and 9.2 respectively. In our study, liver 
biopsy was not realized, so we have compared the results obtained 
of various tests by measuring their respective concordance (kappa 
index).The most consistent results were those of the APRI and Fib-
4, followed by those of Fibroscan Forns, then Fibroscan and APRI. 
These results were classified as moderate despite the small size of 
our patients. It’s will be probably better by including an important 
workforce. In our series, eight cirrhosis cases have been confirmed. 
In these patients, Fibroscan was better than others scores in 
detecting severe fibrosis with a sensitivity at 62.5% and a specificity 
at 95.2%.These results are consistent with the literature data. The 






In this study, 27% of patients infected with HCV had cirrhosis. This 
reflects the severity of the liver disease in this population. In 
hemodialysis patients, the noninvasive tests could be a suitable 
alternative to assess hepatitic fibrosis, given the higher risk of 
bleeding in liver biopsy. Despite the small sample of this work, the 
correlation between biological scores and Fibroscan was generally 










All the authors have contributed to this manuscript in ways that 
comply to ICMJE authorship criteria. All the authors have read and 





Table 1: Thresholds for each test in the diagnosis of significant 
fibrosis  
Table 2: Assessment of the liver fibrosis by non invasive methods 
(n=29)  
Table 3: Correlation between biological scores and Fibroscan for 





1. Consolo F, Freni MA. Nosography and immunopathogenesis of 
viral hepatitis. Nephron. 1992; 61(3):251-4. PubMed | 
Google Scholar  
 
2. Nousbaum JB, Cadranel JF, Bonnemaison G, Bourlière M, 
Chiche L, Chor H, et al. Recommandation pour la pratique 
clinique pour la réalisation de PBH. Gastroenterol Clin Biol. 
2002; 26(10):848-878. PubMed | Google Scholar  
 
3. Imbert-Bismuth F, Ratziu V, Pieroni L, Charlotte F, Benhamou 
Y, Poinard T. Biochemical markers of liver fibrosis in patients 
with hepatitis C virus infection: a prospective study. Lancet. 
20; 357(9262): 1069-75. PubMed | Google Scholar  
 
4. Poynard T, Imbert-Bismuth F, Munteanu M, Messous D, Myers 
RP, Thabut D et al. Overview of the diagnostic value of 
biochemeical markers of fibrosis (Fibrotest, HCV Fibrosure) and 
necrosis (Actitest) in patients with chronic hepatitis C. 
Comparative Hepatology. 2004; 3(1): 8. PubMed | Google 
Scholar  
 
5. Calès P, Oberti, F, Michalak S, Hubert-Fouchard I, Rousselet 
MC, Konaté A et al. A novel panel of blood markers to assess 
the degree of liver fibrosis. Hepatology. 2005; 42(6): 1373-81. 
PubMed | Google Scholar  
 
6. Beaugrand M. Fibroscan: instructions for use. Gastroenterol 
Clin Biol. 2006; 30(4):513514. PubMed | Google Scholar  
 
7. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, 
Conjeevaram HS, Lok AS. A simple noninvasive index can 
predict both significant fibrosis and cirrhosis in patients with 
chronic hepatitis C. Hepatology. 2003; 38(2):518-526. 
PubMed | Google Scholar  
 
8. Forns X, Ampurdanes S, Lovet JM, Aponte J, Quinto L, 
Martinez-Bauer E, Bruguera M et al. Identification of chronic 
hepatitis C patients without hepatic fibrosis by a simple 
predictive model. Hepatology. 2002; 36(4 pt 1):986-992. 
PubMed | Google Scholar  
 
9. Schiavon L, Schiavon JLN, Carvalho Filho RJ et al. Simple Blood 
Tests as Non invasive Markers of Liver Fibrosis in Hemodialysis 
Patients with Chronic Hepatitis C Virus Infection. Hepatology. 
2007; 46(2):307-314. PubMed | Google Scholar  
 
10. Chen HL, Cheng CL, Chun JL et al. The ratio of 
aminotransferase to platelets is a useful index for predicting 
hepatic fibrosis in hemodialysis patients with chronic hepatitis 
C. Kidney international. 2010; 78(1):103-109. PubMed | 
Google Scholar  
 
11. Forns X, Ampurdanes S, Lovet JM, Aponte J, Quinto L, 
Martinez-Bauer E et al. Identification of chronic hepatitis C 
patients without hepatic fibrosis by a simple predictive model. 
Hepatology. 2002; 36(4 pt 1):986-992. PubMed | Google 
Scholar  
 
12. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner 
J et al. Development of a simple noninvasive index to predict 
significant fibrosis in patients with HIV/HCV coinfection. 
Hepatology. 2006; 43(6):1317-25. PubMed | Google Scholar  
 
13. Foucher J. Assessment of cirrhosis and its severity by 
FibroScan and biochemical markers in alcoholic patiens. J 
Hepatol. 2006; 44:S39. PubMed | Google Scholar  
 
14. Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving 
practices of non-invasive markers of liver fibrosis in patients 
with chronic hepatitis C in France: time for new guidelines. J 





Page number not for citation purposes 4 
15. Lee MH, Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Yang 
JM et al. Comparison of surrogate serum markers and transient 
elastography (Fibroscan) for assessing cirrhosis in patients with 
chronic viral hepatitis. Dig Dis Sci. 2010; 55(12):3552-3560. 
PubMed | Google Scholar  
 
16. Haute autorité de santé. Méthodes non invasives de mesure de 
la fibrose hépatique, actualisation. 2008. Maroc. Haute autorité 
de santé. Google Scholar  
 
17. Tsochatzis E.A, Gurusamy K.S, Ntaoula S, Cholongitas E, 
Davidson BR, Burroughs AK. Elastography for the diagnosis of 
severity of fibrosis in chronic liver disease: A Meta-analysis of 
diagnostic accuracy. Journal of Hepatology. 2011; 54(4):650-9. 
PubMed | Google Scholar  
 
18. Liu CH, Liang CC, Hung KW, Liu CJ, Chen SI, Lin JW et Al. 
Transient Elastography to Assess Hepatic Fibrosis in 
Hemodialysis Chronic Hepatitis C Patients. Clin Am J Nephrol 





Table 1: thresholds for each test in the diagnosis of significant fibrosis (6-
9) 
  Non significant fibrosis Significant fibrosis 
Fibroscan <7.1 kpa >7.1 kpa 
APRI <0.4 >0.95 
Forns <4.2 >6.9 




Table 2: assessment of the liver fibrosis by non invasive methods (n=29) 
  Non significant Fibrosis intermediate area Significant Fibrosis 
Fibroscan 23 0 6 
APRI 18 8 3 
Fib4 12 12 5 




Table 3: Correlation between biological scores and 
Fibroscan for fibrosis evaluation  
Scores kappa Accord 
APRI-Forns 0.088 Bad 
APRI-Fib 4 0.492 Moderate 
Forns- Fib 4 0.322 Moderate 
Fibroscan- APRI 0.432 Moderate 
Fibroscan- Fib 4 0.273 Moderate 
Fibroscan- Forns 0.476 Moderate 
  
 
 
 
 
 
 
